Table 4 Summary of subgroup and sensitivity analysis of eligible studies included in a meta-analysis of prolonged infusion versus intermittent infusion of β-lactams in hospitalized patients†
Sub-group analysis | Studies Included | Mortality Risk Ratio (95% CI) | I2 % | Studies Included | Clinical Cure Risk Ratio (95% CI) | I2% |
|---|---|---|---|---|---|---|
β-lactam subclasses | ||||||
Penicillins | 2 | 0.62 (0.19-2.03) | 0 | 3 | 0.77 (0.46-1.30) | 0 |
Cephalosporins | 4 | 0.95 (0.35-2.63) | 50 | 8 | 1.04 (0.92-1.18) | 35 |
Carbapenems | 2 | 1.08 (0.64-1.82) | 0 | 2 | 1.00 (0.69-1.44) | 0 |
Continuous infusion | 6 | 0.80 (0.42-1.50) | 22 | 10 | 1.01 (0.92-1.10) | 16 |
Not funded by pharmaceutical industry | 5 | 0.80 (0.37-1.73) | 26 | 5 | 1.15 (0.85-1.57) | 57 |
Equivalent daily dose of β-lactam antibiotic | 5 | 1.30 (0.59-2.87) | 0 | 6 | 1.06 (0.90-1.25) | 48 |
Sensitivity-analysis | ||||||
Intention-to-treat analysis | 8 | 1.10 (0.75-1.60) | 0 | 8 | 1.05 (0.93-1.19) | 21 |